EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SARS‐COV‐2 infection and Parkinson's disease: Possible links and perspectives

Hayder M Al-Kuraishy, Ali I Al-Gareeb, Ajeet Kaushik iD, Małgorzata Kujawska iD, Eman A Ahmed iD, Gaber El-Saber Batiha

Journal of Neuroscience Research · 2023

DOI: 10.1002/jnr.25171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuroscience Research, 2023. Verfasst von Hayder M Al-Kuraishy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq. Hauptthemen laut MEDLINE: Parkinson Disease, COVID-19. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The hallmarks are the presence of Lewy bodies composed mainly of aggregated α‐synuclein and immune activation and inflammation in the brain. The neurotropism of SARS‐CoV‐2 with induction of cytokine storm and neuroinflammation can contribute to the development of PD. Interestingly, overexpression of α‐synuclein in PD patients may limit SARS‐CoV‐2 neuroinvasion and degeneration of dopaminergic neurons; however, on the other hand, this virus can speed up the α‐synuclein aggregation. The review aims to discuss the potential link between COVID‐19 and the risk of PD, highlighting the need for further studies to authenticate the potential association. We have also overviewed the influence of SARS‐CoV‐2 infection on the PD course and management. In this context, we presented the prospects for controlling the COVID‐19 pandemic and related PD cases that, beyond global vaccination and novel anti‐SARS‐CoV‐2 agents, may include the development of graphene‐based nanoscale platforms offering antiviral and anti‐amyloid strategies against PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseCOVID-19Humansalpha-SynucleinPandemicsSARS-CoV-2Dopaminergic Neurons

Stichwörter der Autor:innen

COVID-19Parkinson's diseaseSARS-CoV-2graphene-based nanomaterialsneuroinflammationα-synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq.
  • NanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, Florida, USA.
  • Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
  • Department of Pharmacology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
  • Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.

ORCID-Profile: Ajeet Kaushik, Małgorzata Kujawska, Eman A Ahmed

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Al-Kuraishy, H. M., Al-Gareeb, A. I., Kaushik, A., Kujawska, M., Ahmed, E. A., & Batiha, G. E. (2023). SARS‐COV‐2 infection and Parkinson's disease: Possible links and perspectives. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.25171

Vancouver

Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GE. SARS‐COV‐2 infection and Parkinson's disease: Possible links and perspectives. Journal of Neuroscience Research. 2023. doi:10.1002/jnr.25171

BibTeX
@article{AlKuraishy2023,
  author = {Al-Kuraishy, Hayder M and Al-Gareeb, Ali I and Kaushik, Ajeet and Kujawska, Małgorzata and Ahmed, Eman A and Batiha, Gaber El-Saber},
  title = {SARS‐COV‐2 infection and Parkinson's disease: Possible links and perspectives},
  journal = {Journal of Neuroscience Research},
  year = {2023},
  doi = {10.1002/jnr.25171}
}
Kostenlos starten →